Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity

被引:164
作者
Costa, LG
Cole, TB
Vitalone, A
Furlong, CE
机构
[1] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98105 USA
[2] Univ Bari, Dept Pharmacol & Human Physiol, Bari, Italy
[3] Univ Washington, Dept Med & Genome Sci, Div Med Genet, Seattle, WA 98195 USA
关键词
organophosphates; paraoxonase (PON1); PON1; status; genetic susceptibility; biomarkers;
D O I
10.1016/j.cccn.2004.09.019
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Organophosphorus (OP) compounds are still among the most widely used insecticides, and their main mechanism of acute toxicity is associated with inhibition of acetylcholinesterase. Measurements of urine metabolites and of blood cholinesterase activity are established biomarkers of exposure to OPs and of early biological effects. In recent years, increasing attention has been given to biomarkers of susceptibility to OP toxicity. Here we discuss the polymorphisms of paraoxonase (PON1), a liver and serum enzyme that hydrolyzes a number of OP compounds, and its role in modulating the toxicity of OPs. We stress the importance of determining PON1 status, which encompasses the PON1(192)Q/R polymorphism (that affects catalytic ability toward different substrates) and PON1 levels (which are modulated in part by a C-108T polymorphism) over straight genotyping. Epidemiological studies on OP-exposed workers that include assessment of PON1 status to validate in human populations the role of PON1 as a determinant of susceptibility to OPs, as indicated by animal studies, are needed. Documentation of exposure and of early health effects would be most relevant to increase the predictive value of the test. (C) 2004 Elsevier B.V All rights reserved.
引用
收藏
页码:37 / 47
页数:11
相关论文
共 72 条
[61]  
Ray DE, 1998, TOXICOL LETT, V103, P527
[62]  
Richter R. J., 2004, CURRENT PROTOCOLS TO
[63]   Determination of paraoxonase (PON1) status requires more than genotyping [J].
Richter, RJ ;
Furlong, CE .
PHARMACOGENETICS, 1999, 9 (06) :745-753
[64]   Pathophysiology of the intermediate syndrome of organophosphorus poisoning [J].
Sedgwick, EM ;
Senanayake, N .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1997, 62 (02) :201-202
[65]   NEUROTOXIC EFFECTS OF ORGANOPHOSPHORUS INSECTICIDES - AN INTERMEDIATE SYNDROME [J].
SENANAYAKE, N ;
KARALLIEDDE, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (13) :761-763
[66]   Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis [J].
Shih, DM ;
Gu, LJ ;
Xia, YR ;
Navab, M ;
Li, WF ;
Hama, S ;
Castellani, LW ;
Furlong, CE ;
Costa, LG ;
Fogelman, AM ;
Lusis, AJ .
NATURE, 1998, 394 (6690) :284-287
[67]   Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids -: Apolipoprotein A-I stabilizes activity [J].
Sorenson, RC ;
Bisgaier, CL ;
Aviram, M ;
Hsu, C ;
Billecke, S ;
La Du, BN .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (09) :2214-2225
[68]   A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression [J].
Suehiro, T ;
Nakamura, T ;
Inoue, M ;
Shiinoki, T ;
Ikeda, Y ;
Kumon, Y ;
Shindo, M ;
Tanaka, H ;
Hashimoto, K .
ATHEROSCLEROSIS, 2000, 150 (02) :295-298
[69]  
*USEPA, 2002, PEST IND SAL US 1998, P33
[70]  
*USEPA, 2000, US DAT CHOL INH RISK, P50